Use of DNA methyltransferase inhibitor and poly(adenosine diphosphate ribose) polymerase inhibitor (PARPi) in the treatment of PARPi-resistant, high-grade serous ovarian cancer

被引：0
作者：
Shafa, Anousheh [1 ]
Hou, Xiaonan [1 ]
Wang, Liewei [1 ]
Weroha, S. John [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
GYNECOLOGIC ONCOLOGY | 2024年 / 190卷
关键词：
D O I：
10.1016/j.ygyno.2024.07.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1275
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [1] Combination therapy with decitabine and olaparib in poly(ADP-ribose) polymerase inhibitor (PARPi) resistant high grade serous ovarian cancer
    Shafa, A.
    Hou, X.
    Wang, L.
    Weroha, S. J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S54 - S54
  • [2] Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
    Madariaga, Ainhoa
    Bowering, Valerie
    Ahrari, Soha
    Oza, Amit M.
    Lheureux, Stephanie
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (07) : 903 - 915
  • [3] Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer
    Dottino, Joseph A.
    Esselen, Katharine M.
    Costa, Rebecca
    Argetsinger, Stephanie
    Shahzad, Mahnum
    Ross-Degnan, Dennis
    Wagner, Anita K.
    VALUE IN HEALTH, 2024, 27 (09) : 1175 - 1178
  • [4] Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer
    Harrison, Ross F.
    Fu, Shuangshuang
    Sun, Charlotte C.
    Zhao, Hui
    Lu, Karen H.
    Giordano, Sharon H.
    Meyer, Larissa A.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 225 (01) : 68.e1 - 68.e11
  • [5] PARP inhibitor (PARPi) rechallenge shows differential sensitivity in PARPi olaparibresistant BRCA1-mutated (BRCA1m) high-grade serous ovarian cancer (HGSC)
    Shih, Chi-Ting
    Huang, Tzu-Ting
    Nair, Jayakumar R.
    Lee, Jung-Min
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Combination of the PARP1-selective inhibitor AZD5305 with the ATR inhibitor ceralasertib for the treatment of PARPi-resistant cancer
    Albertella, Mark
    Wijnhoven, Paul
    Demin, Annie
    Illuzzi, Giuditta
    Ropero, Andrea Herencia
    Serra, Violeta
    Karmokar, Ankur
    Staniszewska, Anna
    Lau, Alan
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [7] Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study
    Cerda, Victoria R.
    Lu, Diana
    Scott, Marla
    Kim, Kenneth H.
    Rimel, Bobbie Jo
    Kamrava, Mitchell
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (02) : 153 - 158
  • [8] Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival
    Gan, Alex
    Green, Andrew R.
    Nolan, Christopher C.
    Martin, Stewart
    Deen, Suha
    HUMAN PATHOLOGY, 2013, 44 (08) : 1638 - 1647
  • [9] Poly Adenosine Diphosphate (ADP)-Ribose Polymerase (PARP) Inhibitor in the Management of Recurrent Ovarian Carcinosarcoma
    Yeoh, S.
    Oehler, M.
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2019, 59 : 63 - 63
  • [10] C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer
    Jiahong Tan
    Xu Zheng
    Mengchen Li
    Fei Ye
    Chunyan Song
    Cheng Xu
    Xiaoxue Zhang
    Wenqian Li
    Ya Wang
    Shaoqing Zeng
    Huayi Li
    Gang Chen
    Xiaoyuan Huang
    Ding Ma
    Dan Liu
    Qinglei Gao
    Oncogene, 2021, 40 : 3845 - 3858
12345